COVID-19 Impact on Schizophrenia Therapeutics Market, Global Research Reports 2020-2021
Schizophrenia therapeutics are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.
The second-generation antipsychotic drugs segment accounted for the majority market shares because these drugs involve less side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called as atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improves the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This in turn, will boost the segment’s growth throughout the estimated period.
This report provides a complete quantitative data and qualitative analysis on the global market for Schizophrenia Therapeutics. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Schizophrenia Therapeutics was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Schizophrenia Therapeutics is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Schizophrenia Therapeutics, including the following market information:
Global Schizophrenia Therapeutics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Schizophrenia Therapeutics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Schizophrenia Therapeutics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Schizophrenia Therapeutics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Alkermes, AbbVie, Amgen, Bristol-Myers Squibb, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
First-Generation Antipsychotic Drugs
Second-Generation Antipsychotic Drugs
Third-Generation Antipsychotic Drugs
Based on the Application:
Hospitals
Clinics
Other
The second-generation antipsychotic drugs segment accounted for the majority market shares because these drugs involve less side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called as atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improves the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This in turn, will boost the segment’s growth throughout the estimated period.
This report provides a complete quantitative data and qualitative analysis on the global market for Schizophrenia Therapeutics. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Schizophrenia Therapeutics was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Schizophrenia Therapeutics is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Schizophrenia Therapeutics, including the following market information:
Global Schizophrenia Therapeutics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Schizophrenia Therapeutics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Schizophrenia Therapeutics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Schizophrenia Therapeutics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Alkermes, AbbVie, Amgen, Bristol-Myers Squibb, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
First-Generation Antipsychotic Drugs
Second-Generation Antipsychotic Drugs
Third-Generation Antipsychotic Drugs
Based on the Application:
Hospitals
Clinics
Other
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
